title: Comparative efficacy and side effects of the treatment of euthyroid goiter with levo-thyroxine or triiodothyroacetic acid.
abstract: Euthyroid goiter is usually treated with TSH-inhibitory doses of levo-T(4) (L-T(4)). Because triiodothyroacetic acid (TRIAC) decreases TSH levels, the following study was perfomed: 36 euthyroid goitrous female patients (no cancer or chronic thyroiditis) were randomized to TRIAC (19.6 micro g/kg) (n = 19) or L-T4 (1.7 microg/kg) (n = 17) treatment during 11 months. Goiter volume; lumbar and femoral bone mineral density; serum osteocalcin; deoxypyridinoline; TSH; free T(4); total, high-density lipoprotein, and low-density lipoprotein cholesterol; and triglycerides were measured before and after the study period. Student's t test and chi(2) analysis were performed. TSH values (microunits per milliliter) in the TRIAC and L-T(4) groups were: 1.91 +/- 0.6 (basal) and 0.180 +/- 0.1 (after) and 2.1 +/- 2.5 (basal) and 0.180 +/- 0.3 (after), respectively. Thyroid volume decreased 37.9 +/- 35.4% in the TRIAC patients and 14.5 +/- 39.5% in the L-T(4) group (P = 0.069). Forty-two percent of the goiters with TRIAC reduced more than 50% their initial volume vs. 17.7% with L-T(4) (P = 0.15). With TRIAC, patients experienced fewer side effects. No differences in the changes of bone mineral density, serum deoxypyridinoline, osteocalcin, or the lipid profile were observed between both groups. The present results show that TRIAC is more effective than L-T(4) in the reduction of goiter size, with comparable effects on peripheral parameters.
authors: Department of Endocrinology and Metabolism, French Hospital, Buenos Aires, Argentina.
authors: G
authors: G
authors: Brenta
authors: M
authors: M
authors: Schnitman
authors: O
authors: O
authors: Fretes
authors: E
authors: E
authors: Facco
authors: M
authors: M
authors: Gurfinkel
authors: S
authors: S
authors: Damilano
authors: N
authors: N
authors: Pacenza
authors: A
authors: A
authors: Blanco
authors: E
authors: E
authors: Gonzalez
authors: M A
authors: MA
authors: Pisarev
mesh_terms: D000328:Adult; D001794:Blood Pressure; D001842:Bone and Bones / Q000378:metabolism; D006042:Goiter / Q000188:drug therapy* / Q000473:pathology; D006339:Heart Rate; D006801:Humans; D007037:Hypothyroidism / Q000188:drug therapy / Q000473:pathology; D008099:Liver / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D013960:Thyroid Function Tests; D013974:Thyroxine / Q000008:administration & dosage* / Q000009:adverse effects*; D016896:Treatment Outcome; D014284:Triiodothyronine / Q000008:administration & dosage* / Q000009:adverse effects* / Q000031:analogs & derivatives*
chemical_list: D014284:Triiodothyronine; C010642:3,3',5-triiodothyroacetic acid; D013974:Thyroxine